https://doi.org/10.4081/aiua.2021.3.301
Testicular germ cells tumors in adolescents and young adults: Management and outcomes from a single-center experience
Submitted: March 10, 2021
Accepted: May 7, 2021
Published: September 30, 2021
Accepted: May 7, 2021
Abstract Views: 943
PDF: 362
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Objective: To investigate and compare the effectiveness of active surveillance versus post-surgical active treatment, in patients with testicular germ cells tumor (TGCT).
Materials and methods: We retrospectively analyzed 52 patients who underwent surgery for TGCT from January 2009 to December 2014. All the patients were divided into two age groups: the Group A included children-adolescents from 18 months to 21 years old, while the Group B comprised young adults from 22 to 39 years old. Clinical, histopathological, therapeutic and follow-up data were collected.
Results: Overall, 22 patients (42,3%) were enrolled in the Group A and 30 patients (57.7%) were categorized in the Group B. Inguinal orchiectomy was performed in all patients. Retroperitoneal lymphadenectomy was performed in 4 patients (7.7%). Post-surgical management differed based on clinical stage, resulting in active surveillance or adjuvant therapy. After an average 7 years follow-up period (range: 3.5-9.0 years), the overall survival rate is 100%. The relapse risk is significantly higher for the patients in the Group B, displaying a recurrence free-survival rate of 72% versus 95% (Group A); 11 relapses (21.1%) were recorded 2 years after surgery. Of these, 3 recurrences (12.0%) occurred in patients undergoing an active surveillance approach, while 8 (29.6%) in patients subjected to an active treatment.
Conclusions: The excellent prognosis in both age groups confirms the high curability of this neoplasia. The active surveillance could represent an optimal option for low recurrence risk tumors. However, post-surgical treatments should be taken into consideration for TGCT with high risk factors, including tumor size, lymphovascular and rete testis invasion.
Hayes-Lattin B, Bleyer A. “Testicular Cancer” in Cancer in adolescents and young adults. Springer Publishing AG, 2017.
DOI: https://doi.org/10.1007/978-3-319-33679-4_12
Ehrlich Y, Margel D, Lubin MA, et al. Advances in the treatment of testicular cancer. Transl Androl Urol. 2015;4:381-90.
Guzzinati S, Buzzoni C, De Amgelis R, et al. ARTUM working group. Cancer prevalence in Italy: an analysis of geographic variability. Cancer Causes Control, 2012; 23:1497-510.
DOI: https://doi.org/10.1007/s10552-012-0025-8
Shen AH, Howell D, Edwards E, et al. The experience of patients with early-stage testicular cancer during the transition from active treatment to follow-up surveillance. Urol Oncol. 2016; 34:168.e11-20.
DOI: https://doi.org/10.1016/j.urolonc.2015.09.016
McGlynn KA, Trabert B. Adolescent and adult risk factors for testicular cancer. Nature Reviews Urology. 2012;9:339-49.
DOI: https://doi.org/10.1038/nrurol.2012.61
Chien FL, Schwartz SM, Johnson RH. Increase in testicular germ cell tumor incidence among hispanic adolescents and young adults in the United States. Cancer 2014; 120:2728-34.
DOI: https://doi.org/10.1002/cncr.28684
Schmiedel S, Schuz J, Skakkebaek NE, et al. Testicular germ cell cancer incidence in an immigration perspective, Denmark, 1978 to 2003. The J Urol. 2010; 183:1378.
DOI: https://doi.org/10.1016/j.juro.2009.12.058
Erin L. Marcotte, Pankratz N, Amatruda J Fetal. Variants in BAK1, SPRY4 and GAB2 are Associated with pediatric germ cell tumors: are port from the children’s oncology group. Genes Chromosomes Cancer. 2017; 56:548-558.
DOI: https://doi.org/10.1002/gcc.22457
Le Cornet C, Fervers B, Pukkala E, et al. Parental occupational exposure to organic solvents and testicular germ cell tumors in their offspring: NORD-TEST study. Environ Health Perspect. 2017;125:067023.
DOI: https://doi.org/10.1289/EHP864
Turnbull C, Rapley EA, Seal S, et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet. 2010; 42:604-7.
DOI: https://doi.org/10.1038/ng.607
DeRouen MC, Mujahid M, Srinivas S, et al. Disparities in adolescent and young adult survival after testicular cancer vary by histologic subtype: a population-based study in California 1988-2010. J Adolesc Young Adult Oncol. 2016; 5:31-40.
DOI: https://doi.org/10.1089/jayao.2015.0041
Leslie SW, Villanueva CA. Cryptorchidism. In Stat Pearls, Treasure Island (FL)-Stat Pearls Publishing 2018.
Shaw PH, Reed DR, Yeager N, et al. Adolescent and young adult (AYA) oncology in the United States: a specialty in its late adolescence. J Pediatr Hematol Oncol. 2015; 37:161-9.
DOI: https://doi.org/10.1097/MPH.0000000000000318
Hisamatsu E, Takagi S, Nakagawa Y, et al. Prepubertal testicular tumors: A 20-year experience with 40 cases. Int J Urol. 2010;17:956-9.
DOI: https://doi.org/10.1111/j.1442-2042.2010.02629.x
Sobin LH, Gospodarowicz MK, Wittekind Ch. TNM Classification of Malignant Tumors, International Union Against Cancer. 2009.
Albers P, Albrecht W, Algaba F, et al. European Association of Urology. Guidelines on Testicular Cancer: 2015 Update. Eur Urol. 2015; 68:1054-68.
DOI: https://doi.org/10.1016/j.eururo.2015.07.044
Oldenburg J, Fosså SD, Nuver J, et al. ESMO Guidelines Working Group. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi125-32.
DOI: https://doi.org/10.1093/annonc/mdt304
Tryakin A, Fedyanin M, Bulanov A, et al. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status. J Cancer Res Clin Oncol. 2018; 144:1817-1823.
DOI: https://doi.org/10.1007/s00432-018-2695-4
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4.
Boccellino M, Vanacore D, Zappavigna S, et al. Testicular cancer from diagnosis to epigenetic factors. Oncotarget, 2017; 8:104654-104663.
DOI: https://doi.org/10.18632/oncotarget.20992
Abhomela M. Pediatric Testicular Cancer: two decades of Saudi national data. Urol Ann. 2017; 9:310-314.
DOI: https://doi.org/10.4103/UA.UA_79_17
Chung JM, Lee SD. Overview of pediatric testicular tumors in Korea. Korean Journal of Urology. 2014; 55:789-96.
DOI: https://doi.org/10.4111/kju.2014.55.12.789
Sun H, Kim P, Jia P, et al. Distinct telomere length and molecular signatures in seminoma and non-seminoma of testicular germ cell tumor. Brief Bioinform. 2019; 20:1502-1512.
DOI: https://doi.org/10.1093/bib/bby020
Nistal M, Paniagua R, González-Peramato P, et al. Perspective in pediatric pathology, Chapter 25. Testicular and paratesticular tumors in the pediatric age group. Pediatr Dev Pathol. 2016; 19:471-492.
DOI: https://doi.org/10.2350/16-09-1829-PER.1
Hoffman HA, Toshkezi G, Fullmer JM, et al. Pitfalls in diagnosis and management of testicular choriocarcinoma metastatic to the brain: report of 2 cases and review of literature. World Neurosurgery. 2017; 106:536-542.
DOI: https://doi.org/10.1016/j.wneu.2017.07.023
Murray MJ, Huddart RA, Coleman N. The present and future of serum diagnostic tests for testicular germ cell tumors. Nat Rev Urol. 2016; 13:715-725.
DOI: https://doi.org/10.1038/nrurol.2016.170
Romo Muñoz MI, Núñez Cerezo V, Dore Reyes M, et al. Tumores testiculares en la edad pediátrica: indicaciones de la cirugía conservadora [Testicular tumours in children: Indications for testissparing surgery]. An Pediatr (Engl Ed). 2018; 88:253-258.
DOI: https://doi.org/10.1016/j.anpedi.2017.05.009
Kamran SC, Seisen T, Markt SC, et al. Contemporary treatment patterns and outcomes for clinical stage IS testicular cancer. Eur Urol. 2018; 73:262-270.
DOI: https://doi.org/10.1016/j.eururo.2017.06.013
Ehrlich Y, Beck SD, Foster RS, et al. Serum tumor markers in testicular cancer. Urol Oncol. 2013; 31:17-23.
DOI: https://doi.org/10.1016/j.urolonc.2010.04.007
Gumus M, Bilici A, Odabas H, et al. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB non seminomatous testicular germ cell tumors. World J Urol. 2017;35:1103-1110.
DOI: https://doi.org/10.1007/s00345-016-1964-6
Alanee S, Nicholson A, Slaton J. Contemporary treatment of low risk stage I non-seminomatous germ cell testicular tumors: a survey of the society of Urologic Oncology. Urol. Oncol. 2012; 30:749-51.
DOI: https://doi.org/10.1016/j.urolonc.2011.05.017
Patel HD, Srivastava A, Alam R, et al. Radiotherapy for stage I and II testicular seminomas: secondary malignancies and servival. Urol Oncol. 2017; 35:606.e1- e7.
DOI: https://doi.org/10.1016/j.urolonc.2017.06.051
Leveridge MJ, Siemens DR, Brennan K, et al. Temporal trends in management and outcomes of testicular cancer: A population-based study. Cancer. 2018; 124:2724-2732.
DOI: https://doi.org/10.1002/cncr.31390
Nappi L, Nichols CR, Kollmannsberger CK. New treatments for stage I testicular cancer. Clinical Adv Hematol Oncol. 2017; 15:626-631.
Nayan M, Jewett MAS, Hosni A, et al. Conditional risk of relapse in surveillance for clinical stage I testicular cancer. Eur Urol. 2017;71:120-127.
DOI: https://doi.org/10.1016/j.eururo.2016.07.013
Richie JP. Cardiovascular Disease Mortality after chemotherapy or surgery for testicular non seminoma:a population-based study. J Urol. 2016; 196:1448-1449.
DOI: https://doi.org/10.1016/j.juro.2016.08.057
Yilmaz A, Cheng T, Zhang J, Trpkov K. Testicular hilum and vascular invasion predict advanced clinical stage in nonseminomatous germ cell tumors. Mod Pathol. 2013; 26:579-86.
DOI: https://doi.org/10.1038/modpathol.2012.189
Cohn-Cedermark G, Stahl O, Tandstad T. SWENOTECA. Surveillance vs.adjuvant therapyof clinical stage I testicular tumors-a review and the SWENOTECA experience. Andrology. 2015; 3:102-10.
DOI: https://doi.org/10.1111/andr.280
Smart, Lopes, Rice S, et al. Chemotherapy drugs cyclophosphamide, cisplatin and Doxorubicin induce germ cell loss in an in vitro model of the prepubertal testis. Sci Rep. 2018; 8:1773.
DOI: https://doi.org/10.1038/s41598-018-19761-9
Chung P, Warde P. Contemporary management of stage I and II seminoma. Curr Urol Rep. 2013; 14:525-33.
DOI: https://doi.org/10.1007/s11934-013-0365-2
How to Cite
Spinelli, C., Cito, G., Morelli, G., Ghionzoli, M. ., Bertocchini, A., Sanna, B. ., Galli, L., Antonuzzo, A., Morganti, R., & Strambi, S. (2021). Testicular germ cells tumors in adolescents and young adults: Management and outcomes from a single-center experience. Archivio Italiano Di Urologia E Andrologia, 93(3), 301–306. https://doi.org/10.4081/aiua.2021.3.301
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.